Revive Therapeutics (RVVTF) Regulatory Update Archive.
April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as...
Citius (CTXR). Dang Flippers!
Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
And We Have Our First MEME Stock! $2.00 to $29.95.
Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention (Bloomberg)
Guess we were bound to stumble across...
Can This Diabetes Drug Make you Smarter?
OKAY, maybe not make you smarter, but a new study out today says it may delay the onset of dementia - so...
Citius Pharma (CTXR). Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update
$36.9 million in cash and cash equivalents as of December 31, 2022 ; runway through February 2024
Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).
Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR)
Summary
Orchestra BioMed™ Announces Global Strategic Partnership with Terumo Corporation.
Orchestra BioMed™ Announces Global Strategic Partnership with Terumo Corporation for Development and Commercialization of Virtue® Sirolimus-Eluting Balloon.
June 13,...
Citius (CTXR) and Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
GeoVax (GOVX) Research Reports Archive
Research Report Archive
Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research....
Adding ENDRA Life Sciences (NDRA) $0.89 to Watch List.
Another Fatty Liver Idea. This Time a Play on Detecting Fatty Liver Non-Invasively. Heads Up. Nearing Resistance at $0.89.